Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.

Cipolla, B G; Ziade, J; Bansard, J Y; Moulinoux, J P; Staerman, F; Quemener, V; Lobel, B; Guillé, F

Cipolla, B G; Ziade, J; Bansard, J Y; Moulinoux, J P; Staerman, F; Quemener, V; Lobel, B; Guillé, F.

Affiliation

Cipolla BG; Department of Urology, Université de Rennes, France.

Cancer ; 78(5): 1055-65, 1996 Sep 01.

Article in En | MEDLINE | ID: mdl-8780544

Subject(s)

Erythrocytes/chemistry; Neoplasm Recurrence, Local/blood; Prostatic Neoplasms/blood; Spermine/blood; Aged; Aged, 80 and over; Androgen Antagonists/therapeutic use; Bone Neoplasms/secondary; Follow-Up Studies; Gonadotropin-Releasing Hormone/analogs & derivatives; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local/mortality; Neoplasm Recurrence, Local/therapy; Orchiectomy; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen/analysis; Prostatic Neoplasms/mortality; Prostatic Neoplasms/therapy; Survival Rate

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Spermine / Erythrocytes / Neoplasm Recurrence, Local Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Cancer Year: 1996 Type: Article Affiliation country: France

Search on Google

XML

PubMed Links